Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlledtrial
Although higher baseline HbA 1c predictably associates with greater glycaemic reductions, the marked heterogeneity in response (as visualised in Fig
This research gap reflects the challenging regulatory landscape for peptides and the lack of pharmaceutical industry interest in compounds that cannot be patented
The truth is that some patients may stop treatment early due to unpleasant side effects, such as nausea, digestive discomfort, and more
Marketed & Imported By: Baljit Nutrition Stores Pvt Ltd C-102/A28 Phase-7 Mohali, Contact - 9888431075 OR Ammolabz, Plot No.1541, JLPL Industrial Park, Sector-82, Mohali -140308 Punjab Email id - [email protected] Contact - 9855613414